Drug General Information |
Drug ID |
D0YP4A
|
Former ID |
DNC006937
|
Drug Name |
(5-pyridin-3-yl-furan-2-yl)methanethiol
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C10H9NOS
|
Canonical SMILES |
C1=CC(=CN=C1)C2=CC=C(O2)CS
|
InChI |
1S/C10H9NOS/c13-7-9-3-4-10(12-9)8-2-1-5-11-6-8/h1-6,13H,7H2
|
InChIKey |
GLMNDKCXHHOKIQ-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Cytochrome P450 3A4 |
Target Info |
Inhibitor |
[1]
|
Cytochrome P450 2D6 |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
Linoleic acid metabolism
|
Retinol metabolism
|
Metabolism of xenobiotics by cytochrome P450
|
Drug metabolism - cytochrome P450
|
Drug metabolism - other enzymes
|
Metabolic pathways
|
Bile secretion
|
Chemical carcinogenesishsa00980:Metabolism of xenobiotics by cytochrome P450
|
Serotonergic synapse
|
PathWhiz Pathway
|
Caffeine Metabolism
|
Retinol Metabolism
|
Reactome
|
Xenobiotics
|
Aflatoxin activation and detoxificationR-HSA-211981:Xenobiotics
|
WikiPathways
|
Metapathway biotransformation
|
Aflatoxin B1 metabolism
|
Estrogen metabolism
|
Benzo(a)pyrene metabolism
|
Tamoxifen metabolism
|
Tryptophan metabolism
|
Oxidation by Cytochrome P450
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
Nuclear Receptors Meta-Pathway
|
Farnesoid X Receptor Pathway
|
Vitamin D Receptor Pathway
|
Felbamate Metabolism
|
Lidocaine metabolism
|
Nifedipine Activity
|
Colchicine Metabolic Pathway
|
Irinotecan Pathway
|
Drug Induction of Bile Acid Pathway
|
Fatty Acid Omega Oxidation
|
Codeine and Morphine MetabolismWP702:Metapathway biotransformation
|
Aripiprazole Metabolic Pathway
|
Codeine and Morphine Metabolism
|
References |
REF 1 | J Med Chem. 2006 Nov 30;49(24):6987-7001.Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. |